Top Markets
#1 Black Phoenix Black Phoenix +355.27%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +62.66%
#4 OpenEden OpenEden +56.84%
#5 Akedo Akedo +56.63%
#6 BasedHype BasedHype +27.37%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +20.66%
#9 Acurast Acurast +19.36%
#10 Humanity Humanity +17.61%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Kedudukan dalam Saham #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Harga Saham
$0.01292666
Disegerakkan terakhir: 2025-04-08
Modal Pasaran
$157.54K
Perubahan (1 hari)
6.84%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan Synairgen plc (SNG)

Kategori

Healthcare
Bilangan saham terbitan bagi Synairgen plc (SNG)
Bilangan saham terbitan setakat June 2024: 201.38M
Menurut laporan kewangan terkini dan harga saham Synairgen plc, bilangan saham terbitan semasa ialah 201.38M. Pada akhir December 2022, syarikat mempunyai 201.36M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Synairgen plc (SNG) dari 2004 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
2026 (TTM) 201.38M 0.00%
2023 201.38M 0.01%
2022 201.36M 0.46%
2021 200.44M 36.24%
2020 147.12M 33.64%
2019 110.09M 15.56%
2018 95.26M 1.15%
2017 94.18M 2.48%
2016 91.90M 0.64%
2015 91.32M 3.77%
2014 88.00M 16.35%
2013 75.64M 4.37%
2012 72.47M 19.66%
2011 60.56M 0.77%
2010 60.10M 154.94%
2009 23.57M 8.03%
2008 21.82M -9.98%
2007 24.24M 1.94%
2006 23.78M 26.20%
2005 18.84M 85.90%
2004 10.14M 0.00%
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 26.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -69.12%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -100.00%
BE